[{"id":"17d5dfd7-684d-4f90-850e-e14953c32f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04091867","created_at":"2021-01-18T20:01:30.016Z","updated_at":"2025-02-25T12:37:25.866Z","phase":"Phase 1","brief_title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","source_id_and_acronym":"NCT04091867","lead_sponsor":"University of Colorado, Denver","biomarkers":" EPHB4","pipe":" | ","alterations":" EGFR expression • CDKN2A negative","tags":["EPHB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • carboplatin • sEphB4-HSA"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 01/06/2020","start_date":" 01/06/2020","primary_txt":" Primary completion: 05/14/2021","primary_completion_date":" 05/14/2021","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2025-02-24"},{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"e6b99f28-6a26-4cf9-aa0c-52200cf1061c","acronym":"ECOG-ACRIN EA3202","url":"https://clinicaltrials.gov/study/NCT05063552","created_at":"2021-10-01T12:54:14.078Z","updated_at":"2025-02-25T12:28:23.682Z","phase":"Phase 2/3","brief_title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","source_id_and_acronym":"NCT05063552 - ECOG-ACRIN EA3202","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/15/2027","primary_completion_date":" 12/15/2027","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2025-02-24"},{"id":"f99d43e2-a88e-46e7-9ba6-67aaeb1cdec6","acronym":"RTOG 1216","url":"https://clinicaltrials.gov/study/NCT01810913","created_at":"2021-01-18T08:01:55.190Z","updated_at":"2025-02-25T13:52:01.448Z","phase":"Phase 2/3","brief_title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","source_id_and_acronym":"NCT01810913 - RTOG 1216","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["EGFR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • Datalai (cetuximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 613","initiation":"Initiation: 03/22/2013","start_date":" 03/22/2013","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-20"},{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"99f591b9-7e23-4ea7-a5a0-fe1e2287e1db","acronym":"KEYNOTE-F21","url":"https://clinicaltrials.gov/study/NCT04225117","created_at":"2021-01-18T20:34:06.535Z","updated_at":"2025-02-25T15:18:27.870Z","phase":"Phase 2","brief_title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","source_id_and_acronym":"NCT04225117 - KEYNOTE-F21","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" BRAF • ER • ALK • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive","tags":["BRAF • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 329","initiation":"Initiation: 03/09/2020","start_date":" 03/09/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-12"},{"id":"cb11626b-0801-40b0-ae65-d3f235f68f1d","acronym":"Iintune-1","url":"https://clinicaltrials.gov/study/NCT04420884","created_at":"2021-01-18T21:18:09.463Z","updated_at":"2025-02-25T15:18:40.036Z","phase":"Phase 1/2","brief_title":"A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04420884 - Iintune-1","lead_sponsor":"Takeda","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • dazostinag (TAK-676)"],"overall_status":"Recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 01/15/2026","primary_completion_date":" 01/15/2026","study_txt":" Completion: 01/15/2026","study_completion_date":" 01/15/2026","last_update_posted":"2025-02-12"},{"id":"696d727b-575b-4b42-9ab7-71058751cfe0","acronym":"NCI-2021-13902","url":"https://clinicaltrials.gov/study/NCT05172258","created_at":"2021-12-29T13:53:34.637Z","updated_at":"2025-02-25T16:32:39.281Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","source_id_and_acronym":"NCT05172258 - NCI-2021-13902","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ipatasertib (RG7440) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/26/2022","start_date":" 07/26/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-07"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"7a0a4fa0-562c-4834-ae83-73683d4790a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04852328","created_at":"2021-04-21T11:53:27.797Z","updated_at":"2025-02-25T16:38:23.751Z","phase":"Phase 2","brief_title":"Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma","source_id_and_acronym":"NCT04852328","lead_sponsor":"Washington University School of Medicine","biomarkers":" CDKN2A • CD8 • IFNG","pipe":" | ","alterations":" CDKN2A expression","tags":["CDKN2A • CD8 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CUE-101"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-06"},{"id":"cd4a12b9-e599-4c99-ab46-15deaa409d08","acronym":"","url":"https://clinicaltrials.gov/study/NCT03811015","created_at":"2021-01-18T18:49:56.370Z","updated_at":"2025-02-25T16:37:19.650Z","phase":"Phase 3","brief_title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","source_id_and_acronym":"NCT03811015","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 636","initiation":"Initiation: 08/16/2019","start_date":" 08/16/2019","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-06"},{"id":"79ecaaae-3f94-4fc7-b7cc-99e9b10ae5f7","acronym":"PROLoNg","url":"https://clinicaltrials.gov/study/NCT05815927","created_at":"2023-04-18T15:04:33.044Z","updated_at":"2025-02-25T16:18:43.213Z","phase":"Phase 3","brief_title":"Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer","source_id_and_acronym":"NCT05815927 - PROLoNg","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 03/15/2025","start_date":" 03/15/2025","primary_txt":" Primary completion: 07/15/2027","primary_completion_date":" 07/15/2027","study_txt":" Completion: 03/30/2030","study_completion_date":" 03/30/2030","last_update_posted":"2025-02-05"},{"id":"ba15135a-7176-4f0e-a8cc-e6c040cf6509","acronym":"","url":"https://clinicaltrials.gov/study/NCT04574583","created_at":"2021-01-18T21:50:28.241Z","updated_at":"2025-02-25T17:00:40.932Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta \"Trap\"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)","source_id_and_acronym":"NCT04574583","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 02/07/2023","primary_completion_date":" 02/07/2023","study_txt":" Completion: 05/19/2023","study_completion_date":" 05/19/2023","last_update_posted":"2025-02-03"},{"id":"80d8b063-fde0-450d-9857-f3e96ed43e05","acronym":"STELLAR-305","url":"https://clinicaltrials.gov/study/NCT06082167","created_at":"2023-10-14T01:13:13.670Z","updated_at":"2025-02-25T16:19:12.483Z","phase":"Phase 2/3","brief_title":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06082167 - STELLAR-305","lead_sponsor":"Exelixis","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-01-31"},{"id":"d78d7b46-d2cc-485a-8c04-81f9d73189d4","acronym":"KEYNOTE-E28","url":"https://clinicaltrials.gov/study/NCT04429542","created_at":"2021-01-18T21:20:02.191Z","updated_at":"2025-02-25T16:10:23.024Z","phase":"Phase 1","brief_title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","source_id_and_acronym":"NCT04429542 - KEYNOTE-E28","lead_sponsor":"Bicara Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-27"},{"id":"6a9e85c6-7cd7-4897-9939-6e11b554b3de","acronym":"","url":"https://clinicaltrials.gov/study/NCT03715946","created_at":"2023-12-07T21:16:08.964Z","updated_at":"2025-02-25T14:27:44.132Z","phase":"Phase 2","brief_title":"Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer","source_id_and_acronym":"NCT03715946","lead_sponsor":"Robert L. Ferris, MD, PhD","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 11/16/2018","start_date":" 11/16/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2025-01-13"},{"id":"08da958b-deab-46fd-9448-9e7d0dc1d817","acronym":"KEYNOTE B84","url":"https://clinicaltrials.gov/study/NCT04815720","created_at":"2021-03-25T11:52:15.829Z","updated_at":"2025-02-25T16:11:18.429Z","phase":"Phase 1/2","brief_title":"Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT04815720 - KEYNOTE B84","lead_sponsor":"Vaccinex Inc.","biomarkers":" PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1","pipe":"","alterations":" ","tags":["PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pepinemab (VX15)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 07/24/2024","primary_completion_date":" 07/24/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-01-08"},{"id":"b40fb89a-d042-4bf3-862c-f905fdac4d70","acronym":"VERSATILE-002","url":"https://clinicaltrials.gov/study/NCT04260126","created_at":"2021-01-18T20:42:10.407Z","updated_at":"2025-02-25T16:09:57.311Z","phase":"Phase 2","brief_title":"Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC","source_id_and_acronym":"NCT04260126 - VERSATILE-002","lead_sponsor":"PDS Biotechnology Corp.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Versamune HPV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-12-18"},{"id":"7541215a-5741-4ef5-b1af-d11fad045e6c","acronym":"KEYNOTE-E72","url":"https://clinicaltrials.gov/study/NCT06016920","created_at":"2023-08-30T14:08:44.837Z","updated_at":"2025-02-25T16:19:04.091Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06016920 - KEYNOTE-E72","lead_sponsor":"Nykode Therapeutics ASA","biomarkers":" PD-L1 • IFNG","pipe":"","alterations":" ","tags":["PD-L1 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • abipapogene suvaplasmid (VB10.16)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 12/19/2023","start_date":" 12/19/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-12-17"},{"id":"aea0f58d-10bb-4911-b89f-8864936129e3","acronym":"CA224-056","url":"https://clinicaltrials.gov/study/NCT04080804","created_at":"2021-01-18T19:58:51.916Z","updated_at":"2025-02-25T14:28:37.614Z","phase":"Phase 2","brief_title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","source_id_and_acronym":"NCT04080804 - CA224-056","lead_sponsor":"Dan Zandberg","biomarkers":" TMB • LAG3","pipe":" | ","alterations":" CD8 positive","tags":["TMB • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-12-13"},{"id":"b69ba720-deab-42dc-9517-e6067c868218","acronym":"OSCC","url":"https://clinicaltrials.gov/study/NCT06728618","created_at":"2025-02-26T10:02:49.401Z","updated_at":"2025-02-26T10:02:49.401Z","phase":"Phase 2","brief_title":"Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma","source_id_and_acronym":"NCT06728618 - OSCC","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-12-11"},{"id":"20ec0814-6de7-4db9-a034-30ef491a8c51","acronym":"","url":"https://clinicaltrials.gov/study/NCT05526924","created_at":"2022-09-02T17:00:19.091Z","updated_at":"2025-02-25T16:27:01.989Z","phase":"Phase 1","brief_title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","source_id_and_acronym":"NCT05526924","lead_sponsor":"University of Chicago","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-11-22"},{"id":"a93ec7ac-af54-43ee-8608-d8c37dfbf77a","acronym":"DEPEND","url":"https://clinicaltrials.gov/study/NCT03944915","created_at":"2025-02-26T07:16:24.948Z","updated_at":"2025-02-26T07:16:24.948Z","phase":"Phase 2","brief_title":"De-Escalation Therapy for Human Papillomavirus Negative Disease","source_id_and_acronym":"NCT03944915 - DEPEND","lead_sponsor":"University of Chicago","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • paclitaxel • 5-fluorouracil • hydroxyurea • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/26/2019","start_date":" 08/26/2019","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-08-15"},{"id":"d34f9c68-d289-4614-b7bb-c24b096c0e1b","acronym":"KEYCHAIN","url":"https://clinicaltrials.gov/study/NCT03383094","created_at":"2025-02-25T16:07:22.270Z","updated_at":"2025-02-25T16:07:22.270Z","phase":"Phase 2","brief_title":"Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer","source_id_and_acronym":"NCT03383094 - KEYCHAIN","lead_sponsor":"Loren Mell, MD","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 03/15/2018","start_date":" 03/15/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-08-06"}]